EA201400521A1 - Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения - Google Patents

Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения

Info

Publication number
EA201400521A1
EA201400521A1 EA201400521A EA201400521A EA201400521A1 EA 201400521 A1 EA201400521 A1 EA 201400521A1 EA 201400521 A EA201400521 A EA 201400521A EA 201400521 A EA201400521 A EA 201400521A EA 201400521 A1 EA201400521 A1 EA 201400521A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
methods
receiving
medicines containing
indicated
Prior art date
Application number
EA201400521A
Other languages
English (en)
Other versions
EA025158B1 (ru
EA025158B9 (ru
Inventor
Армин Хеккель
Сара Фраттини
Дитер Хампрехт
Йёрг Клей
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201400521A1 publication Critical patent/EA201400521A1/ru
Publication of EA025158B1 publication Critical patent/EA025158B1/ru
Publication of EA025158B9 publication Critical patent/EA025158B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

В заявке описаны соединения общей формулы (I)и их таутомеры и соли, предпочтительно их фармацевтически приемлемые соли с неорганическими или органическими кислотами и основаниями, которые обладают ценными фармакологическими характеристиками, в особенности ингибирующим воздействием на эпителиальные натриевые каналы, их применение для лечения заболеваний, в особенности заболеваний легких и дыхательных путей.
EA201400521A 2011-11-02 2012-10-29 Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения EA025158B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02
PCT/EP2012/071352 WO2013064450A1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Publications (3)

Publication Number Publication Date
EA201400521A1 true EA201400521A1 (ru) 2014-09-30
EA025158B1 EA025158B1 (ru) 2016-11-30
EA025158B9 EA025158B9 (ru) 2018-03-30

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400521A EA025158B9 (ru) 2011-11-02 2012-10-29 Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения

Country Status (34)

Country Link
US (4) US8759349B2 (ru)
EP (1) EP2773633B1 (ru)
JP (1) JP6091513B2 (ru)
KR (1) KR102006612B1 (ru)
CN (2) CN104024244B (ru)
AP (1) AP2014007670A0 (ru)
AU (1) AU2012331274B2 (ru)
BR (1) BR112014010583A2 (ru)
CA (1) CA2854217C (ru)
CL (1) CL2014001047A1 (ru)
CO (1) CO6940429A2 (ru)
CY (1) CY1120974T1 (ru)
DK (1) DK2773633T3 (ru)
EA (1) EA025158B9 (ru)
EC (1) ECSP14001929A (ru)
ES (1) ES2645744T3 (ru)
GE (2) GEAP201813485A (ru)
HR (1) HRP20171614T1 (ru)
HU (1) HUE034929T2 (ru)
IL (1) IL232035A (ru)
LT (1) LT2773633T (ru)
ME (1) ME02905B (ru)
MX (1) MX348522B (ru)
NO (1) NO2773633T3 (ru)
PE (1) PE20141607A1 (ru)
PH (1) PH12014500970B1 (ru)
PL (1) PL2773633T3 (ru)
PT (1) PT2773633T (ru)
RS (1) RS56498B1 (ru)
SG (1) SG11201401907TA (ru)
SI (1) SI2773633T1 (ru)
TN (1) TN2014000180A1 (ru)
UA (1) UA115868C2 (ru)
WO (1) WO2013064450A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
HRP20171614T1 (hr) * 2011-11-02 2017-12-01 Boehringer Ingelheim International Gmbh Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
CA2915633A1 (en) * 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
EP3019492B1 (en) * 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP6217866B2 (ja) * 2014-10-24 2017-10-25 小野薬品工業株式会社 Kcnq2〜5チャネル活性化剤
WO2016112120A1 (en) * 2015-01-07 2016-07-14 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (ru) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
CA2378181A1 (en) 1999-07-19 2001-01-25 Richard C. Boucher, Jr. Conjugates of sodium channel blockers and methods of using the same
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
KR20070059063A (ko) 2004-08-18 2007-06-11 마이클 알 존슨. 지방족 아미드 및 에스테르 피라지노일구아니딘 나트륨채널 차단제
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2658813A1 (en) * 2006-07-24 2008-01-31 International Stem Cell Corporation Synthetic cornea from retinal stem cells
KR20100005730A (ko) * 2007-05-07 2010-01-15 노파르티스 아게 유기 화합물
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
JP2011520831A (ja) * 2008-05-13 2011-07-21 ノバルティス アーゲー 3,5−ジアミノ−6−クロロ−ピラジン−2−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
PL2723176T3 (pl) 2011-06-27 2018-01-31 Parion Sciences Inc Chemicznie i metabolicznie stabilny dipeptyd o silnej aktywności blokera kanału sodowego
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HRP20171614T1 (hr) * 2011-11-02 2017-12-01 Boehringer Ingelheim International Gmbh Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
CN104024231A (zh) 2011-11-02 2014-09-03 勃林格殷格翰国际有限公司 制备酰基胍和酰基硫脲化合物的新方法

Also Published As

Publication number Publication date
ES2645744T3 (es) 2017-12-07
DK2773633T3 (da) 2017-11-13
JP6091513B2 (ja) 2017-03-08
US20150336933A1 (en) 2015-11-26
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
HUE034929T2 (en) 2018-03-28
GEP20186880B (en) 2018-07-25
CY1120974T1 (el) 2019-12-11
TN2014000180A1 (en) 2015-09-30
US8759349B2 (en) 2014-06-24
PE20141607A1 (es) 2014-11-23
CN106279110B (zh) 2019-12-10
SI2773633T1 (sl) 2017-11-30
HK1196819A1 (zh) 2014-12-24
AU2012331274A1 (en) 2014-04-03
US9920035B2 (en) 2018-03-20
JP2014534222A (ja) 2014-12-18
KR20140085498A (ko) 2014-07-07
NO2773633T3 (ru) 2017-12-30
US20140228374A1 (en) 2014-08-14
UA115868C2 (uk) 2018-01-10
HRP20171614T1 (hr) 2017-12-01
WO2013064450A1 (en) 2013-05-10
MX348522B (es) 2017-06-16
US20180194747A1 (en) 2018-07-12
AU2012331274B2 (en) 2017-06-08
BR112014010583A2 (pt) 2020-04-22
RS56498B1 (sr) 2018-01-31
CO6940429A2 (es) 2014-05-09
LT2773633T (lt) 2017-11-10
IL232035A (en) 2017-05-29
IL232035A0 (en) 2014-05-28
AP2014007670A0 (en) 2014-05-31
CA2854217A1 (en) 2013-05-10
PT2773633T (pt) 2017-11-14
CN104024244B (zh) 2016-09-14
ME02905B (me) 2018-10-20
PH12014500970B1 (en) 2017-10-06
EA025158B1 (ru) 2016-11-30
US20130109697A1 (en) 2013-05-02
PH12014500970A1 (en) 2014-06-09
CN106279110A (zh) 2017-01-04
SG11201401907TA (en) 2014-05-29
KR102006612B1 (ko) 2019-08-02
GEAP201813485A (en) 2018-04-10
MX2014005166A (es) 2014-05-28
CA2854217C (en) 2019-12-31
CL2014001047A1 (es) 2014-11-07
EP2773633B1 (en) 2017-08-02
EP2773633A1 (en) 2014-09-10
ECSP14001929A (es) 2015-11-30
EA025158B9 (ru) 2018-03-30
CN104024244A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
UA115320C2 (uk) Інгібітори кінази
EA201491671A1 (ru) Гетероциклильные соединения
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201792116A1 (ru) Ингибитор янус-киназы
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
UA104489C2 (ru) Соединения для лечения дислипидемии и родственных болезней
EA201591195A1 (ru) Новые хинолоновые производные
CO6361926A2 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
EA201690888A1 (ru) Новые гетероциклические соединения
PH12014501278A1 (en) Kinase inhibitors
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
EA201490750A1 (ru) Применение глутарилгистамина для лечения заболеваний дыхательных путей
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний
EA201400522A1 (ru) Новый способ получения ацилгуанидинов и ацилтиомочевин
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
TN2014000218A1 (en) Kinase inhibitors
TH134961A (th) อนุพันธ์ควินาโซลีนสำหรับการรักษาการติดเชื้อไวรัสและโรคเพิ่มเติม
AR088107A1 (es) Derivados de anilinopirimidina y su uso como inhibidores de quinasas p38
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
TH154903A (th) อนุพันธ์แอลคิลไพริมิดีนสำหรับการรักษาการติดเชื้อไวรัสและโรคอื่นๆ

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU